AGP Executive Report
Last update: 10 hours agoCancer Care Evidence: A Mount Sinai retrospective in JAMA Otolaryngology found neoadjuvant chemoimmunotherapy (NACI) drove far higher deep pathologic response in resectable HNSCC than immunotherapy alone (67% vs 3.6%), with especially strong results in HPV-associated disease. FDA & Cardiovascular: LIB Therapeutics’ Lerochol got FDA approval for a self-administered autoinjector and an updated label showing LDL lowering with PCSK9 inhibitor add-on to statins reduces major cardiovascular events. FDA & Cell Therapy: AbelZeta Pharma’s prizlon-cel CAR T therapy won FDA IND clearance for relapsed/refractory large B-cell lymphoma, using a CD20/CD19 bispecific design aimed at reducing antigen-negative relapse. Drug Pricing Pressure: A survey says nearly half of Medicare Part D beneficiaries feel they’re paying more for price-negotiated drugs, with many also reporting access friction like prior authorization. Healthcare Access on the Ground: CalOptima’s street medicine program is expanding to four more Orange County cities to bring primary and behavioral care to people experiencing homelessness. Digital Health Pilot: The FDA selected Cadence for the TEMPO digital health pilot to generate real-world outcomes data for its AI hypertension management software. Workforce & Care Delivery: A VA OIG investigation tied a 2025 work-from-home mandate to a radiologist “mass exodus,” contributing to MRI and CT backlogs that were later addressed.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
